GLP-1 receptor agonists × all-cause mortality

SynthesisBMC medicine2025

The adverse effects associated with semaglutide use in patients at increased risk of cardiovascular events: a systematic review with meta-analysis and Trial Sequential Analysis.

Christina Dam Bjerregaard Sillassen et al.PubMed ↗Full text ↗Publisher ↗

  • Semaglutide (oral or subcutaneous)looks good hereFewer deaths.Randomised, large.

What the trial testedrandomised · 54,972 people · 2025

Randomised vs placebo

Reduced deaths

−15%−21% to −9%

semaglutide (oral or subcutaneous) vs placebo

Bigger than 5 in 10 for all-cause mortality

As reported

RR 0.85, 95% CI 0.79–0.91 · the paper's word: all-cause mortality

Who was studied, and how

54,972people with cardiovascular disease, in this paper

The trial randomly assignedassigned by chance

semaglutide (oral or subcutaneous)
placebo

Reduced deaths−15%

randomised

the abstract, start to end

all-cause mortality (relative risk (RR) 0.85; 95% CI 0.79 to 0.91; I

← favours treatmentfavours comparator →
could be chance
All-cause mortalitysemaglutide (oral or subcutaneous) vs placebo
RR 0.850.79–0.91
GLP-1 receptor agonistsAll-cause mortality

GLP-1 receptor agonists × all-cause mortalityhelps?replicated

unlikelylikely
0.88not counted
← favours treatmentfavours comparator →
more certainless certain
1 / 6

3 papers cite it

2025
2026
this paperpooled itcites it
Full record →Abstract, authors, funding and every citing paper · PMID 41286875